Indivior PLC Stock

Equities

INDV

GB00BN4HT335

Pharmaceuticals

Market Closed - London S.E. 11:35:03 2024-06-14 EDT 5-day change 1st Jan Change
1,318 GBX +3.37% Intraday chart for Indivior PLC +3.05% +11.22%
Sales 2024 * 1.27B 1.74B Sales 2025 * 1.42B 1.96B Capitalization 2.24B 3.08B
Net income 2024 * 268M 368M Net income 2025 * 341M 468M EV / Sales 2024 * 1.54 x
Net cash position 2024 * 287M 394M Net cash position 2025 * 587M 806M EV / Sales 2025 * 1.16 x
P/E ratio 2024 *
8.99 x
P/E ratio 2025 *
6.9 x
Employees 1,000
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.69%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.37%
1 week+3.05%
Current month-8.79%
1 month-6.26%
3 months-19.19%
6 months+7.15%
Current year+11.22%
More quotes
1 week
1 267.00
Extreme 1267
1 337.00
1 month
1 266.00
Extreme 1266
1 485.00
Current year
1 159.00
Extreme 1159
1 770.00
1 year
1 125.00
Extreme 1125
1 938.00
3 years
718.00
Extreme 718
2 020.00
5 years
164.50
Extreme 164.5
2 020.00
10 years
104.90
Extreme 104.9
2 523.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 11-12-31
Director of Finance/CFO - 11-12-31
Compliance Officer - 18-09-30
Members of the board TitleAgeSince
Chairman 65 19-10-31
Director/Board Member 64 22-05-31
Director/Board Member 61 21-03-23
More insiders
Date Price Change Volume
24-06-14 1,318 +3.37% 293,123
24-06-13 1,275 -1.77% 317,675
24-06-12 1,298 -0.92% 414,785
24-06-11 1,310 -0.30% 407,601
24-06-10 1,314 +2.74% 336,552

Delayed Quote London S.E., June 14, 2024 at 11:35 am

More quotes
Indivior PLC is a pharmaceutical company. The Company develops medicines to treat addiction and serious mental illnesses. The Company focuses on building a portfolio of opioid dependence treatments. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Its product pipeline focuses on development and discovery of non-opioid treatment strategies for opioid use disorder (OUD), as well as therapies to address the needs of people suffering from alcohol, stimulant, and cannabis use disorders. Its Sublocade, Subutex, and Suboxone are used for the treatment of opioid use disorder (OUD). Perseris is used for the treatment of Schizophrenia. The Company's pipeline products include AEF0117, INDV-2000, INDV-1000, RBP-6000, RBP-7000, Buprenorphine Sublingual and Naloxone Film, and Buprenorphine and Naloxone Sublingual Tablet. Its pipeline also includes the Orexin-1 Receptor Antagonist Program.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
16.71 USD
Average target price
30.86 USD
Spread / Average Target
+84.63%
Consensus